Contributors  xi
Preface written by Robin A. Weiss  xv

Global Molecular Epidemiology of HIV: Understanding the
Genesis of AIDS Pandemic
Yutaka Takebe, Rie Uenishi, and Xiaojie Li

I. Chapter Overview  1
II. Introduction  2
III. Genotype Classification of HIVs  4
IV. Global Distribution of HIV Genotypes  9
V. Methods for Identifying HIV Genetic Forms  11
VI. Origin of HIVs and Genesis of HIV-1 Pandemic  13
VII. Biological Significance of HIV-1 Variability and Recombination  14
VIII. Conclusions  18
 References  18
Development of Protease Inhibitors and the Fight with Drug-Resistant HIV-1 Variants

Hiroaki Mitsuya, Kenji Maeda, Debananda Das, and Arun K. Ghosh

I. Chapter Overview 169
II. Introduction 170
III. Targeting Viral Protease 170
IV. The Role of PIs and Challenges in HAART 174
V. "Boosting": A Critical Modification of Clinical Efficacy of PIs 175
VI. Viral Resistance to PIs 176
VII. PIs with Activity Against Drug-Resistant HIV-1 182
VIII. Conclusions 189
References 191

HIV-1 Integrase Inhibitors: Update and Perspectives

Elena A. Semenova, Christophe Marchand, and Yves Pommier

I. Chapter Overview 199
II. Foreword 200
III. Integration: A Crucial Step in the HIV Life Cycle 200
IV. Approaches to Inhibit HIV Integration 210
V. Inhibitors in Clinical Trials 216
VI. Inhibitors in Preclinical Development 217
VII. Perspectives 218
References 219

Topical Microbicides: A Promising Approach for Controlling the AIDS Pandemic via Retroviral Zinc Finger Inhibitors

Jim A. Turpin, Marco L. Schito, Lisa M. Miller Jenkins, John K. Inman, and Ettore Appella

I. Chapter Overview 229
II. The AIDS Pandemic and the Rationale for a Microbicide 230
III. Topical Microbicides in Preclinical Development 232
IV. Characteristics of an Ideal Microbicide 237
V. The Retroviral Zinc Fingers of HIV-1 NCp7 as a Potential Microbicide Target 238
VI. Characteristics of the SAMT Chemotype 240
VII. Application of Thioesters for Microbicides 244
VIII. Target Specificity of the SAMT NCp7 Inhibitors 246
IX. Conclusions 249
X. Addendum 250
References 251
Viral Drug Resistance and Fitness
Miguel E. Quiñones-Mateu, Dawn M. Moore-Dudley, Oyebisi Jegede, Jan Weber, and Eric J. Arts

I. Chapter Overview  257
II. Introduction  258
References  283

Gene Therapy to Induce Cellular Resistance to HIV-1 Infection: Lessons from Clinical Trials
Mauro Giacca

I. Chapter Overview  297
II. Introduction: Do We Need HIV-1 Gene Therapy?  298
III. Gene Therapy of HIV Infection: Lessons from Early Clinical Trials  300
IV. Gene Therapy of HIV Infection: Current Developments  306
V. Gene Therapy for HIV Infection: Where Are We Heading?  314
References  317

Zachary A. Klase, Rachel Van Duyne, and Fatah Kashanchi

I. Chapter Overview  327
II. Introduction  328
III. Viral Targets  329
IV. Cellular/Viral Protein–Protein Interactions  331
V. Viral-Induced Cellular Alterations  343
VI. Other Approaches  351
VII. Conclusion  354
References  355

Rapid Disease Progression to AIDS due to *Simian immunodeficiency virus* Infection of Macaques: Host and Viral Factors
Que Dang and Vanessa M. Hirsch

I. Chapter Overview  369
II. Introduction  370
III. SIV Strain Diversity  371
Nonprimate Models of HIV-1 Infection and Pathogenesis
Viet Hoang, Elizabeth Withers-Ward, and David Camerini

I. Chapter Overview 399
II. Introduction 400
III. SCID-Hu Thy/Liv Mice 401
IV. The hu-PBL-SCID Mouse 405
V. NOD/LtSz-SCID Mice 407
VI. Rag2−/− γC−/− and NOD-SCID γC−/− Mice 408
VII. Humanized Immune Competent Mice and Rats 409
VIII. HIV-1 Tg Mice 410
IX. Rabbit Model of HIV Pathogenesis 412
X. Conclusion 413
   References 413

Perspectives for a Protective HIV-1 Vaccine
Marco Schiavone, Ileana Quinto, and Giuseppe Scala

I. Chapter Overview 423
II. Introduction 424
III. Current Strategies in Developing an HIV-1 Vaccine 429
IV. Concluding Remarks 441
   References 442

Molecular Mechanisms of HIV-1 Vertical Transmission and Pathogenesis in Infants
Nafees Ahmad

I. Chapter Overview 453
II. Introduction 454
III. Timing and Mechanism of HIV-1 Vertical Transmission 456